Bicara Therapeutics Inc. (BCAX) vs Iambic Therapeutics, Inc. (IAM)

Bicara Therapeutics Inc. BCAX 8.61 +5.13%
Iambic Therapeutics, Inc. IAM 10.20 −12.37%

Bicara Therapeutics Inc. and Iambic Therapeutics, Inc. are both Biotechnology companies. Bicara Therapeutics Inc. and Iambic Therapeutics, Inc. are of similar size ($551.7M and $542.0M).

Metric	BCAX	IAM	Biotechnology median
P/E	n/m	—	10.60
P/S	n/m	—	9.40
P/B	1.25	—	2.13
Price to free cash flow	n/m	—	25.18
EV/EBITDA	n/m	—	0.66
EV/Sales	n/m	—	9.02
Earnings yield	(36.00%)	—	(32.88%)
Free cash flow yield	(23.13%)	—	(23.13%)

Metric	BCAX	IAM	Biotechnology median
Gross margin	—	—	68.51%
Operating margin	0.00%	—	0.00%
Net margin	0.00%	—	0.00%
Free cash flow margin	0.00%	—	0.00%
Return on equity	(41.01%)	—	(51.96%)
Return on assets	(38.38%)	—	(46.06%)
Return on invested capital	0.00%	—	0.00%

Metric	BCAX	IAM	Biotechnology median
Revenue growth (TTM)	—	—	6.76%
EPS growth (last fiscal year)	37.78%	—	29.88%
Revenue growth, 5-year CAGR	—	—	9.75%
Net income growth, 5-year CAGR	—	—	0.00%

Metric	BCAX	IAM	Biotechnology median
Debt to equity	0.00	—	0.00
Current ratio	11.59	—	4.97
Net debt to EBITDA	2.67	—	1.01

Metric	BCAX	IAM	Biotechnology median
Dividend yield	—	—	0.41%
Payout ratio	—	—	—

Metric	BCAX	IAM	Biotechnology median
Market cap	541.96m	551.74m	161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack